Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in August 2024. The company will be present at the BTIG virtual Biotechnology Conference from August 5-6 and the Canaccord Genuity 44th Annual Growth Conference in Boston from August 13-14.
CEO John Butler will participate in a fireside chat at the BTIG conference on August 6 at 8:00 am EST. At the Canaccord Genuity conference, Mr. Butler will deliver a presentation on August 14 at 8:30 a.m. EST. Investors can access a webcast of the Canaccord Genuity presentation through Akebia's website after the conference.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica focalizzata sulle malattie renali, ha annunciato la sua partecipazione a due conferenze per investitori in programma ad agosto 2024. La società sarà presente alla Conferenza virtuale sulla Biotecnologia BTIG dal 5 al 6 agosto e alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston dal 13 al 14 agosto.
Il CEO John Butler parteciperà a una chiacchierata informale alla conferenza BTIG il 6 agosto alle 8:00 ora orientale. Alla conferenza di Canaccord Genuity, il signor Butler terrà una presentazione il 14 agosto alle 8:30 ora orientale. Gli investitori possono accedere a una trasmissione in diretta della presentazione di Canaccord Genuity attraverso il sito web di Akebia dopo la conferenza.
Akebia Therapeutics (Nasdaq: AKBA), una empresa biofarmacéutica centrada en enfermedades renales, ha anunciado su participación en dos próximas conferencias para inversores en agosto de 2024. La compañía estará presente en la Conferencia Virtual de Biotecnología de BTIG del 5 al 6 de agosto y en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston del 13 al 14 de agosto.
El CEO John Butler participará en una charla informal en la conferencia de BTIG el 6 de agosto a las 8:00 a.m. EST. En la conferencia de Canaccord Genuity, el Sr. Butler dará una presentación el 14 de agosto a las 8:30 a.m. EST. Los inversores pueden acceder a una transmisión en vivo de la presentación de Canaccord Genuity a través del sitio web de Akebia después de la conferencia.
Akebia Therapeutics (Nasdaq: AKBA)는 신장 질환에 중점을 둔 생명공학 제약 회사로, 2024년 8월에 열리는 두 개의 투자자 회의에 참여할 예정이라고 발표했습니다. 이 회사는 8월 5일부터 6일까지 BTIG 가상 생명공학 회의에 참석하고, 8월 13일부터 14일까지 보스턴에서 열리는 캐너코드 제뉴이티 제44회 연례 성장 회의에도 참여할 것입니다.
CEO 존 버틀러는 8월 6일 오전 8시(EST)에 BTIG 회의에서 면담에 참여할 예정입니다. 캐너코드 제뉴이티 회의에서는 8월 14일 오전 8시 30분(EST)에 발표를 할 것입니다. 투자자들은 회의 이후 아케비아 웹사이트를 통해 캐너코드 제뉴이티 발표의 웹캐스트에 접속할 수 있습니다.
Akebia Therapeutics (Nasdaq: AKBA), une entreprise biopharmaceutique spécialisée dans les maladies rénales, a annoncé sa participation à deux prochaines conférences pour investisseurs en août 2024. L'entreprise sera présente à la Conférence Virtuelle de Biotechnologie BTIG du 5 au 6 août, ainsi qu'à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity à Boston du 13 au 14 août.
Le PDG John Butler participera à une discussion informelle lors de la conférence BTIG le 6 août à 8h00 EST. Lors de la conférence Canaccord Genuity, M. Butler présentera le 14 août à 8h30 EST. Les investisseurs pourront accéder à un webinaire de la présentation de Canaccord Genuity via le site Web d'Akebia après la conférence.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im August 2024 bekannt gegeben. Das Unternehmen wird vom 5. bis 6. August auf der BTIG Virtuellen Biotechnologie-Konferenz und vom 13. bis 14. August auf der 44. Jahrestagung für Wachstum von Canaccord Genuity in Boston vertreten sein.
CEO John Butler wird am 6. August um 8:00 Uhr EST an einem Fireside-Chat auf der BTIG-Konferenz teilnehmen. Auf der Canaccord Genuity-Konferenz wird Herr Butler am 14. August um 8:30 Uhr EST eine Präsentation halten. Investoren können nach der Konferenz über die Website von Akebia auf die Webcast-Präsentation von Canaccord Genuity zugreifen.
- None.
- None.
- BTIG Biotechnology Conference
John Butler, Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6, at 8:00 am EST.
- CG 44th Annual Growth Conference
Mr. Butler will present on Wednesday, August 14 at 8:30 a.m. EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-upcoming-investor-conferences-302208267.html
SOURCE Akebia Therapeutics, Inc.
FAQ
What investor conferences will Akebia Therapeutics (AKBA) attend in August 2024?
When is John Butler, CEO of Akebia Therapeutics (AKBA), scheduled to speak at the BTIG Biotechnology Conference?
What time is Akebia Therapeutics' (AKBA) presentation at the Canaccord Genuity Growth Conference?
How can investors access Akebia Therapeutics' (AKBA) presentation from the Canaccord Genuity conference?
